BRAF and neoplasm: Because of the prevalence of KRAS and BRAF mutations in CRC [39], as well as the involvement of the aforementioned mutations in acquired resistance to therapy [40] we hypothesized that a panRAF inhibitor like LY3009120 would have preclinical activity in this tumor setting.